Table 2. Summary of EC50s from experiments measuring IP1 accumulation and ERK1/2 phosphorylation.
Mutants | EC50 (IP1-Elisa) | EC50 (ERK1/2 activity) | ||
Without L-Phe With L-Phe | With L-Phe | Without L-Phe | With L-Phe | |
WT | 2.9±0.3 | 2.0±0.1* | 3.0±0.1 | 1.9±0.1* |
L173F | 1.2±0.1# | 1.0±0.1 | 2.7±0.1# | 1.6±0.1* |
P221L | 1.1±0.1# | 0.9±0.1 | 2.2±0.3# | 1.7±0.2 |
L173P | 10.7±1.0# | 9.0±0.9 | 14.9±1.0# | 13.5±0.8 |
P221Q | 6.1±0.3# | 4.5±0.4* | 11.9±0.3# | 9.5±0.4* |
HEK293 cells were transiently transfected with the WT CaSR or disease-associated CaSR mutants. Cells were then treated with various levels of [Ca2+]o. The EC50s of [Ca2+]o-IP1 responses and the -[Ca2+]o-ERK1/2 phosphorylation activity responses were obtained from curve fitting using the Hill equation as mentioned in Method. # indicates significance with respect to wild type CaSR, p<0.05 (ANOVA, Dunnett test); * indicates significance with respect to the corresponding mutants in the absence of L-Phe, p<0.05 (two-way ANOVA).